Literature DB >> 8932352

Initial prognostic factors in small-cell lung cancer patients predicting quality of life during chemotherapy. Swiss Group for Clinical Cancer Research (SAKK).

J Bernhard1, C Hürny, M Bacchi, R A Joss, F Cavalli, H J Senn, S Leyvraz, R Stahel, C Ludwig, P Alberto.   

Abstract

The question of whether initial prognostic factors in small-cell lung cancer patients have a predictive value for patients' quality of life (QL) during chemotherapy is addressed in the context of a randomised clinical trial comparing early and late alternating chemotherapy (SAKK protocol 15/84). The relative impact of initial tumour stage and performance status, previous weight loss, sex and age on patient-rated QL was analysed over six chemotherapy cycles in 124-130 patients (according to available QL data) with more than 400 questionnaires. Fatigue/malaise, personal functioning, emotional and general well-being were prospectively selected as QL indicators. Predefined summary measures (average QL score over chemotherapy cycles, 'minimum', 'maximum' and 'final' improvement) were analysed separately by scale in various patient groups. General linear models adjusted for treatment arm and response were used to confirm the univariate findings. Within the overall sample, the average QL scores over six cycles were predicted by initial prognostic factors. Patients with poor prognostic factors reported worse QL. Within a limited sample (with baseline QL), patients with poor prognostic factors reported worse QL at baseline and greater improvement under treatment. Graphical comparison of QL patterns over cycles showed permanent discrimination by levels of prognostic factors. The impact of initial prognostic factors was consistently confirmed in the three analyses. Levels of performance status and weight loss best discriminated QL. Initial tumour stage, performance status and previous weight loss can predict QL in small-cell lung cancer during chemotherapy, even after controlling for response to treatment. Our results may contribute to clinical decision-making with regard to the intensity of chemotherapy and QL outcome, especially in patients with extensive disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8932352      PMCID: PMC2074835          DOI: 10.1038/bjc.1996.606

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Approaches to the analysis of quality of life data: experiences gained from a medical research council lung cancer working party palliative chemotherapy trial.

Authors:  P Hopwood; R J Stephens; D Machin
Journal:  Qual Life Res       Date:  1994-10       Impact factor: 4.147

Review 2.  Quality-of-life and cost-effectiveness assessment in lung cancer.

Authors:  B Bergman; N K Aaronson
Journal:  Curr Opin Oncol       Date:  1995-03       Impact factor: 3.645

Review 3.  Psychosocial issues in lung cancer patients.

Authors:  J Bernhard; P A Ganz
Journal:  Cancer Treat Res       Date:  1995

Review 4.  Preliminary experience with quality of life evaluation in patients with lung cancer.

Authors:  P Hopwood; N Thatcher
Journal:  Oncology (Williston Park)       Date:  1990-05       Impact factor: 2.990

5.  Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.

Authors:  A Coates; V Gebski; J F Bishop; P N Jeal; R L Woods; R Snyder; M H Tattersall; M Byrne; V Harvey; G Gill
Journal:  N Engl J Med       Date:  1987-12-10       Impact factor: 91.245

6.  Assessment of 'quality of life' using a daily diary card in a randomised trial of chemotherapy in small-cell lung cancer.

Authors:  N H Gower; R M Rudd; M C Ruiz de Elvira; S G Spiro; L E James; P G Harper; R L Souhami
Journal:  Ann Oncol       Date:  1995-07       Impact factor: 32.976

7.  Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK).

Authors:  R A Joss; P Alberto; C Hürny; M Bacchi; S Leyvraz; B Thürlimann; T Cerny; G Martinelli; R Stahel; C Ludwig
Journal:  Ann Oncol       Date:  1995-01       Impact factor: 32.976

8.  Information and decision-making preferences of hospitalized adult cancer patients.

Authors:  C G Blanchard; M S Labrecque; J C Ruckdeschel; E B Blanchard
Journal:  Soc Sci Med       Date:  1988       Impact factor: 4.634

9.  Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK).

Authors:  R A Joss; M Bacchi; C Hürny; J Bernhard; T Cerny; G Martinelli; S Leyvraz; H J Senn; R Stahel; P Siegenthaler
Journal:  Ann Oncol       Date:  1995-02       Impact factor: 32.976

10.  A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party.

Authors:  N M Bleehen; D J Girling; D Machin; R J Stephens
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

View more
  4 in total

1.  Relationship between deficits in overall quality of life and non-small-cell lung cancer survival.

Authors:  Jeff A Sloan; Xinghua Zhao; Paul J Novotny; Jason Wampfler; Yolanda Garces; Matthew M Clark; Ping Yang
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

2.  Clinical significance of the cachexia index in patients with small cell lung cancer.

Authors:  Se-Il Go; Mi Jung Park; Gyeong-Won Lee
Journal:  BMC Cancer       Date:  2021-05-17       Impact factor: 4.430

3.  Comparison of generic and lung cancer-specific quality of life instruments for predictive ability of survival in patients with advanced lung cancer.

Authors:  Sultan Eser; Tuncay Göksel; Ahmet Emin Erbaycu; Hakan Baydur; Burcu Başarık; Ayşen Öz Yanık; Kader Kıyar Gürsul; Pınar Çelik; Ebru Çakır Ediz; Osman Hatipoğlu; Bedriye Atay Yayla; Sevin Başer; Erhan Eser
Journal:  Springerplus       Date:  2016-10-21

4.  Quality of life during chemotherapy in lung cancer patients: results across different treatment lines.

Authors:  L M Wintner; J M Giesinger; A Zabernigg; M Sztankay; V Meraner; G Pall; W Hilbe; B Holzner
Journal:  Br J Cancer       Date:  2013-10-03       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.